Published in Oncol Lett on November 10, 2014
Cohort profile: cholangiocarcinoma screening and care program (CASCAP). BMC Cancer (2015) 0.81
The lipocalin protein family: structure and function. Biochem J (1996) 5.24
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut (2002) 4.01
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut (2001) 3.45
Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer (2003) 3.44
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist (2011) 3.05
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut (2012) 2.91
The amino acid sequence of human APOA-I, an apolipoprotein isolated from high density lipoproteins. Biochem Biophys Res Commun (1978) 1.75
Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer (2008) 1.61
Proline and hydroxyproline metabolism: implications for animal and human nutrition. Amino Acids (2010) 1.57
Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46
The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci (2011) 1.30
Tumor markers as a diagnostic key for hilar cholangiocarcinoma. Eur J Med Res (2010) 1.29
Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res (2007) 1.25
Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer (2008) 1.21
Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer (2010) 1.19
Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.15
Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol (2009) 1.12
Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol (2011) 1.12
Intratumoral IL-17⁺ cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol (2012) 1.08
Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease. World J Gastroenterol (2009) 1.05
Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. J Gastroenterol Hepatol (2012) 1.05
Protective effects of alpha 1-antitrypsin on acute lung injury in rabbits induced by endotoxin. Chin Med J (Engl) (2003) 1.04
Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma. Clin Exp Immunol (2010) 1.00
The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus. J Clin Pathol (2004) 0.97
Kinesin 18A expression: clinical relevance to colorectal cancer progression. Int J Cancer (2011) 0.96
Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes. J Biomed Biotechnol (2009) 0.95
Characterization of apolipoprotein A-I as a potential biomarker for cholangiocarcinoma. Eur J Cancer Care (Engl) (2009) 0.95
Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis. Front Med China (2010) 0.94
Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J Gastroenterol (2010) 0.94
Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. J Viral Hepat (2010) 0.92
Risk factors and classifications of hilar cholangiocarcinoma. World J Gastrointest Oncol (2013) 0.92
Differential membrane proteomics using 18O-labeling to identify biomarkers for cholangiocarcinoma. J Proteome Res (2008) 0.92
Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases. Int J Hepatol (2010) 0.92
Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma. Dig Liver Dis (2009) 0.92
Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood group, hepatitis B virus and their synergism. Int J Cancer (2013) 0.92
NQO1 expression correlates with cholangiocarcinoma prognosis. Asian Pac J Cancer Prev (2012) 0.92
Proteomic analysis to identify plasma orosomucoid 2 and kinesin 18A as potential biomarkers of cholangiocarcinoma. Cancer Biomark (2012) 0.92
A novel serum carbohydrate marker on mucin 5AC: values for diagnostic and prognostic indicators for cholangiocarcinoma. Cancer (2011) 0.91
Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am Surg (2010) 0.90
Genes and cholangiocarcinoma. Southeast Asian J Trop Med Public Health (2009) 0.89
Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. J Hepatol (2012) 0.89
FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol (2013) 0.88
CA-S27: a novel Lewis a associated carbohydrate epitope is diagnostic and prognostic for cholangiocarcinoma. Cancer Sci (2013) 0.88
Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival. Int J Oncol (2011) 0.87
Diagnostic significance of overexpression of Golgi membrane protein 1 in prostate cancer. Urology (2012) 0.87
CYP24A1 inhibition facilitates the anti-tumor effect of vitamin D3 on colorectal cancer cells. World J Gastroenterol (2013) 0.87
Effect of antiresorptive therapy on urinary hydroxyproline in postmenopausal osteoporosis. Indian J Clin Biochem (2011) 0.86
Up-regulation of annexin A2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker. Int J Parasitol (2010) 0.85
Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma. Asian Pac J Cancer Prev (2011) 0.84
Elevation of serum γ-glutamyltransferase as a predictor of aggressive tumor behaviors and unfavorable prognosis in patients with intrahepatic cholangiocarcinoma: analysis of a large monocenter study. Eur J Gastroenterol Hepatol (2013) 0.84
Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. Ann Surg Oncol (2013) 0.83
Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma. Parasitol Int (2011) 0.83
A novel carbohydrate antigen expression during development of Opisthorchis viverrini- associated cholangiocarcinoma in golden hamster: a potential marker for early diagnosis. Parasitol Int (2011) 0.83
Heat shock proteins 27 and 70 are potential biliary markers for the detection of cholangiocarcinoma. Am J Pathol (2011) 0.83
Serum α1β-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma. Exp Biol Med (Maywood) (2012) 0.83
Analytical characterization and clinical evaluation of an enzyme-linked immunosorbent assay for measurement of afamin in human plasma. Clin Chim Acta (2013) 0.83
Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK. Anticancer Res (2005) 0.82
Molecular mechanisms of cholangiocarcinoma. World J Gastrointest Pathophysiol (2010) 0.82
The potential role of ORM2 in the development of colorectal cancer. PLoS One (2012) 0.82
Inhibitors of 5-lipoxygenase inhibit expression of intercellular adhesion molecule-1 in human melanoma cells. Acta Pharmacol Sin (2004) 0.81
Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma. Hepatogastroenterology (2009) 0.80
The value of expression of M2-PK and VEGF in patients with advanced gastric cancer. Cell Biochem Biophys (2013) 0.80
Pre-diagnostic levels of adiponectin and soluble vascular cell adhesion molecule-1 are associated with colorectal cancer risk. World J Gastroenterol (2012) 0.79
SPRR2A expression in cholangiocarcinoma increases local tumor invasiveness but prevents metastasis. Clin Exp Metastasis (2013) 0.79
Dysregulation of vitamin D3 synthesis leads to enhanced cholangiocarcinoma growth. Dig Liver Dis (2013) 0.79
KL-6 mucin expression in carcinoma of the ampulla of Vater: association with cancer progression. World J Gastroenterol (2005) 0.79
High serum CA19-9 levels are associated with an increased risk of cholangiocarcinoma in patients with intrahepatic duct stones: a case-control study. Surg Endosc (2013) 0.78
Estrogen is increased in male cholangiocarcinoma patients' serum and stimulates invasion in cholangiocarcinoma cell lines in vitro. J Cancer Res Clin Oncol (2012) 0.78
Increase of exostosin 1 in plasma as a potential biomarker for opisthorchiasis-associated cholangiocarcinoma. Tumour Biol (2013) 0.78
Plasma hydroxyproline, MMP-7 and collagen I as novel predictive risk markers of hepatobiliary disease-associated cholangiocarcinoma. Int J Cancer (2011) 0.78
Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholangiocarcinoma. Tumour Biol (2012) 0.78
Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms. Clin Res Hepatol Gastroenterol (2011) 0.77
Inflammation-based prognostic score is a useful predictor of postoperative outcome in patients with extrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci (2013) 0.77
Epigenetic aberrations in cholangiocarcinoma: potential biomarkers and promising target for novel therapeutic strategies. Asian Pac J Cancer Prev (2012) 0.76
Serum adhesion molecule-1 (ICAM-1) as a potential prognostic marker for cholangiocarcinoma patients. Asian Pac J Cancer Prev (2012) 0.76